London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
You will only have one login account. Registering with multiple accounts is not allowed. Any user found to have more than one account on this site will have all, and any future accounts suspended permanently.
Your email and password must only be used by you. If a post is made under your account, it will be considered that it was posted by yourself.
Your account nickname must not be the same, or contain, listed company names or board members' names.
While debating and discussion is fine, we will not tolerate; rudeness, swearing, insulting posts, personal attacks, or posts which are invasive of another's privacy.
You will not;
discuss illegal or criminal activities.
post any confidential or price sensitive information or that is not public knowledge.
post misleading or false statements regarding the share price and performance. Such posts are deemed as market abuse, and may be reported to the appropriate authorities.
post any private communication, or part thereof, from any other person, including from a member of the board of directors of a listed company. Such posts cannot be verified as true and could be deemed to be misleading.
post any personal details (e.g. email address or phone number).
post live price or level 2 updates.
publish content that is not your original work, or infringes the copyright or other rights of any third party.
post non-constructive, meaningless, one word (or short) non-sense posts.
post links to, or otherwise publish any content containing any form of advertising, promotion for goods and services, spam, or other unsolicited communication.
post any affiliate or referral links, or post anything asking for a referral.
post or otherwise publish any content unrelated to the board or the board's topic.
re-post premium share chat posts on regular share chat.
restrict or inhibit any other user from using the boards.
impersonate any person or entity, including any of our employees or representatives.
post or transmit any content that contains software viruses, files or code designed to interrupt, destroy or limit the functionality of this website or any computer software or equipment.
If you are going to post non-English, please also post an English translation of your post.
If you are going to post non-English, please also post an English translation of your post.
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium and Verified Members
Premium Members are members that have a premium subscription with London South East and have access to Premium Chat. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Inan, You posted...… QUOTE...…………………. which backs up what i said "... makes no difference to scancell because we have the fall back plan "scientifically approved" ie CRUK and Scancells scientist have successfully adopted the Nanoparticle. delivery system." END QUOTE
My point was it DOESN'T back up what you said!!!!! It is NOT "scientifically proven" (yet) Just reposting your erroneous claptrap will not make it true!
Also, when you say "makes no difference to scancell" I'm afraid it does and will continue to do so. You have to think it through (or read what people are saying on ADVFN if you are unable to think it through yourself.
The original plan was to conduct a combination trial (SCIB1 and KEYTRUDA) across multiple locations based in the USA and the UK, administered by Ichor's Tri-Grid2 system. The USA arm would be overseen by Keith Flaherty, a well known and eminent oncologist in the USA and internationally. (Also associated with Sloane Kettering a much respected organisation) The publicity in the USA may have opened the way to US finance, who knows?
Let's hope that TG2 does get FDA approval at some point and the IND can be resubmitted and an equivalent US trail can commence. This will inevitably incur a lengthy delay. So to say "this makes no difference to Scancell" is I'm afraid completely untrue and very misleading.
"funny how i explained what "scientifically approved " .... then you change the meaning because you want to disrupt the BB"
Well, you have to ask, does correcting erroneous statements and presenting the facts "disrupt the BB" or merely disrupt someone's private agenda?
So allow me to present the facts, the unadulterated truth. From the RNS 20th May 2019:
"We are delighted to announce this important milestone in our partnership with Cancer Research UK, which moves us one step closer to entering the clinic. This new nanoparticle approach to deliver SCIB2 is expected to achieve results that are as effective as, or even better than, electroporation. We believe SCIB2 has the potential to provide a much-needed treatment option for patients suffering from a range of common solid tumours including NSCLC, the most frequent cause of cancer death globally."
Perhaps you overlooked the significance of
"This new nanoparticle approach to deliver SCIB2 is EXPECTED to achieve results that are as effective as, or even better than, electroporation."
I have capitalised "EXPECTED" for clarity. I have also searched the entire RNS and neither the word "scientifically" nor "proven" appear at all let alone together.
So I repeat, your claptrap does not help anyone. I'm sure there are plenty of factual points that can be made to provide some optimism.
It really isn't helpful to anyone that you are continuing to post your claptrap....
"... makes no difference to scancell because we have the fall back plan "scientifically approved" ie CRUK and Scancells scientist have successfully adopted the Nanoparticle. delivery system." There is absolutely NOTHING "scientifically approved" YET! There are PLANS to use nanoparticle at the instigation of CRUK. As yet, we do not know if this has started and we are years away from being able to say "scientifically PROVEN", this is what the trial is for.
"I will stress this is a "device specific " issue " So what? It has a direct impact on Scancell.
"This is not a Scancell issue" It most patently IS!
The US has effectively shut a US company ... makes no difference to scancell because we have the fall back plan "scientifically approved" ie CRUK and Scancells scientist have successfully adopted the Nanoparticle. delivery system.
so we run the phase 2 SCIB1 in the UK, open multiple trial centers and get the data ...that gives Ichor 2 years min to sort out the FDA because that is critical for them, meanwhile at least 2 trials Janseen and Scancell will continue to provide data on the Ichor gun in support of a future IND in the US. I will stress this is a "device specific " issue
"""Whilst there has been extensive dialogue between Ichor and the Agency, a timely resolution to the device-specific questions has yet to be agreed."""
which is what i mentioned in my posts the other day ...
so the delay is over ... data on Keytruda SCIB1 ... will start to feed through soon .. its the data that is important not the location of the trial centers, we gained a bit of Prestige in the US with the US leading the trials .. and IMHO that has not changed as they still are prepared to lead the trials. This is not a Scancell issue
Dalester - I have special powers - just gave you 4 recs somehow ! Good to read your positive view.
Elsewhere some Posters are extremely disappointed that we were not told that the FDA was on the 'critical path' for the UK SCIB1 Combo trial - may be BoD had particular reasons but IMO too, it looks bad. Very bad.
However it IS good that we are out of limbo and the UK trial can progress and save lives and give Scancell some great data we hope. BoD have been forced to tell us now because the Annual Report has to comment on prospects.
I wonder what Martin Dibble our Non-Exec will have to say and what his attitude is ? Whatever the wider issues, I'm glad BoD took a maybe belated decision and let's hope the trial can now proceed - asap.